| 龙 利,石荣书,胡天刚,赵景昊,秦 伟.TACE术联合胸腺肽α1治疗原发性肝癌并发门静脉癌栓的疗效及对免疫功能的影响[J].现代生物医学进展英文版,2021,(5):923-926. |
| TACE术联合胸腺肽α1治疗原发性肝癌并发门静脉癌栓的疗效及对免疫功能的影响 |
| Effect of TACE Combined with Thymosin α1 on Primary Liver Cancer Complicated with Portal Vein Tumor Thrombus |
| Received:August 23, 2020 Revised:September 17, 2020 |
| DOI：10.13241/j.cnki.pmb.2021.05.026 |
| 中文关键词: TACE术 胸腺肽α1 原发性肝癌 门静脉癌栓 肝功能 细胞因子 |
| 英文关键词: TACE Thymosin α1 Primary Liver Cancer Portal Vein Tumor Thrombus Liver Function Cell Factors |
| 基金项目:四川省卫生和计划生育委员会科研基金项目（150087） |
|
| Hits: 782 |
| Download times: 377 |
| 中文摘要: |
| 摘要 目的：研究经肝动脉化疗栓塞术（transcatheter arterial chemoembolization，TACE）联合胸腺肽α1治疗原发性肝癌并发门静脉癌栓的疗效及对免疫功能的影响。方法：选择2018年9月～2020年2月我院的55例原发性肝癌并发门静脉癌栓患者，根据治疗方法分为两组。两组均开展TACE术，观察组联用胸腺肽α1。比较两组的白蛋白（Albumin，ALB）、谷氨酸转氨酶（glutamate aminotransferase，ALT）、总胆红素（total bilirubin，TBIL）、天冬氨酸转氨酶（aspartate aminotransferase，AST）、血清白介素（ interleukin，IL）-4、IL-2和IL-6水平。结果：观察组的有效率明显高于对照组(35.71 % vs 18.52 %，P<0.05)；治疗后，两组的ALB、CD4 +/CD8+、CD3 +、CD4 +水平明显升高(P<0.05)，ALT、TBIL、AST、血清IL-4、IL-2、IL-6水平、CD8 +明显降低(P<0.05)，且观察组上述指标明显优于对照组(P<0.05)。结论：TACE术联合胸腺肽α1对于原发性肝癌并发门静脉癌栓有显著的疗效，能改善其肝功能和免疫功能，降低血清IL-4、IL-2和IL-6水平。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of transcatheter arterial chemoembolization (TACE) combined with thymosin α 1 in the treatment of primary liver cancer complicated with portal vein tumor thrombus and its influence on immune function. Methods: A total of 55 patients with primary liver cancer complicated with portal vein tumor thrombus, who were treated in Affiliated Hospital of Zunyi Medical University from September 2018 to February 2020, were selected and randomly divided into two groups. TACE was performed in both groups, and thymosin α 1 was used in the observation group. The levels of albumin (ALB), glutamic acid transaminase (ALT), total bilirubin (TBIL), aspartate aminotransferase (AST), serum interleukin (IL- 4, IL-2 and IL-6 were compared between the two groups. Results: The effective rate of the observation group was significantly higher than that of the control group (35.71% vs 18.52%, P<0.05); after treatment, the levels of ALB, CD4 +/CD8+, CD3 +, and CD4 + in the two groups were significantly increased (P<0.05). ALT, TBIL, AST, serum IL-4, IL-2, IL-6 levels, and CD8 + were significantly reduced (P<0.05), and the above indicators in the observation group were significantly better than those in the control group (P<0.05). Conclusion: TACE combined with thymosin α 1 has a significant effect on primary liver cancer complicated with portal vein tumor thrombus. It can improve the liver function and immune function, and reduce the serum levels of IL-4, IL-2 and IL-6. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
